Articles related to LUNG CANCER

ASCO 2023 abstracts: a glimpse into groundbreaking advancements in the oncology field. At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Gilead Sciences and Kite Oncology are set to present 30 abstracts. Their data underscores their leadership in hard-to-treat cancers, notably metastatic breast cancer. In addition, they highlight a growing presence in lung cancer and other tumor types. Trodelvy® (sacituzumab govitecan-hziy) emerges as a promising treatment for HR+/HER2- metastatic breast cancer (mBC) with the final overall survival (OS) results from the Phase 3 TROPiCS-02 study. Its efficacy extends to metastatic urothelial cancer (UC) and advanced endometrial cancer, reinforcing its pan-tumor potential. Moreover, Yescarta® (axicabtagene ciloleucel) offers a ray of hope for adult patients with relapsed/refractory large B-cell lymphoma (LBCL). Notably, this CAR T-cell therapy demonstrates a statistical improvement over standard care in overall survival, marking a significant medical breakthrough. Gilead’s oncology pipeline, particularly for lung cancer, is expanding. The ongoing late-stage development program evaluates Trodelvy in non-small cell lung cancer (NSCLC). Also, the updated interim analysis of ARC-7, evaluating domvanalimab in first-line NSCLC, will be presented. Presentations at ASCO 2023 will also share trial updates from ongoing studies in lung cancer, triple-negative breast cancer, UC, and other solid […]

In the realm of lung cancer screening, understanding the right approach for high-risk patients is paramount. This summary navigates through a quiz about lung cancer screening. Centered on a 63-year-old woman, she’s a former smoker. Moreover, she has COPD. The objective is to identify her optimal screening test. Presented are five options. These comprise chest X-ray, PET scan, low-dose CT, sputum cytology, and opting for no screening. Turning to the NLST for guidance, it emerges that one of these has the upper hand. USPSTF, among other societies, backs the method. Importantly, it’s fitting for high-risk groups. Given her age and past smoking habit, the woman meets the criteria. Consequently, it is suggested the woman receives this screening annually. However, screening bears risks. Potential harms span from further tests to patient distress. Additional concerns include overdiagnosis and radiation exposure. Therefore, advanced facilities are ideal for screening. Two of the choices are ruled out. Strikingly, they don’t improve mortality rates. In fact, one of the choices presented isn’t designed for routine screening. Instead, this type of scan evaluates previously identified nodules or masses. Notably, overlooking this type of screening may lead to premature mortality. This particularly holds for high-risk, asymptomatic patients. The […]

Pfizer and Thermo Fisher Scientific have partnered to expand access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in over 30 countries across Latin America, Africa, the Middle East, and Asia. The collaboration aims to address the limited availability of advanced genomic testing in these regions. Local access to NGS testing can provide faster analysis of associated genes, enabling healthcare providers to select the most appropriate therapy for individual patients. Thermo Fisher will identify local laboratories that will use their NGS technology and ensure they meet industry standards, while Pfizer will explore ways to make NGS testing affordable and raise awareness among healthcare providers. The companies plan to expand geographically and extend testing to other types of cancer. The global burden of cancer is expected to rise significantly, with breast and lung cancer being the leading types responsible for millions of deaths worldwide. To improve treatment outcomes, the collaboration seeks to deliver precision insights to underserved patients through rapid NGS testing conducted in decentralized labs closer to where patients are treated. The program aims to provide tailored care for cancer patients worldwide, acknowledging that individualized approaches based on precise disease characteristics are often required. By adopting next-generation […]

The 2023 AACR meeting has seen a large number of clinical abstracts presented, demonstrating that science from the lab is moving to the clinic. Examples include an RNA vaccine from Moderna in combination with pembrolizumab in a neoadjuvant setting in patients with melanoma, and the AEGEAN trial, which looks at perioperative therapy in patients with lung cancer. The conference is also seeing a focus on more diverse speakers, including junior investigators. The field of mRNA cancer vaccines is evolving, with personalised vaccines being used to activate the immune system in combination with checkpoint inhibitors, resulting in positive results in some cancers. The conference is an opportunity to learn about new science, make new connections and collaborations, and gain a better understanding of how to push the field forward.

Significant progress has been made in the last 20 years in the identification of therapeutically relevant oncogenic drivers in NSCLC. These oncogenic drivers have been the focus of targeted medicines that have been created to offer enhanced tailored treatment for NSCLC. To improve the choice of patient-specific treatment, an oral presentation at the 2023 ONA Summit Live Virtual Meeting compared guideline-directed targeted therapies based on patient and tumor characteristics. It also described collaborative strategies for managing therapy-related adverse events for this patient population. Key molecular characteristics in advanced NSCLC were also discussed, along with their relationships to current and emerging targeted therapies.

The article discusses the expanding landscape of targeted therapies for patients with advanced metastatic non-small-cell lung cancer (NSCLC), with nine targetable oncogenes and seven approvals within the last five years. With these emerging therapeutic options, the article emphasizes the importance of understanding the existing data on immune checkpoint inhibitors (ICIs) for each oncogene-driven lung cancer to guide the selection and sequencing of therapeutic options. The article reviews the clinical data on ICIs for each of the driver oncogene-defined lung cancer subtypes, including efficacy, toxicities, and potential strategies to enhance ICI efficacy in oncogene-driven NSCLC.